Related Experiment Video
Updated: May 13, 2026
07:01
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
CD133 expression: a potential prognostic marker for non-small cell lung cancers.
Hidenori Mizugaki1, Jun Sakakibara-Konishi, Junko Kikuchi
1First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
International Journal of Clinical Oncology
|March 13, 2013
Summary
CD133 expression in non-small cell lung cancer (NSCLC) correlates with advanced pathological stages. This finding suggests CD133 may serve as a novel prognostic marker for patients with stages II, III, and IV NSCLC.
Area of Science:
- Oncology
- Cancer Stem Cell Research
- Molecular Pathology
Background:
- CD133 is a transmembrane glycoprotein implicated in cancer stem cell biology.
- Previous studies suggest CD133 expression correlates with poor prognosis in some solid tumors.
- The role of CD133 in non-small cell lung cancer (NSCLC) prognosis remains debated.
Purpose of the Study:
- To investigate the clinicopathological significance of CD133 expression in NSCLC.
- To evaluate the correlation between CD133 expression and patient prognosis in NSCLC.
Main Methods:
- Immunohistochemical assessment of CD133 expression in 161 surgically resected NSCLC specimens.
- Analysis of correlations between CD133 expression and various clinicopathological features, including pathological stage (pStage).
Main Results:
- CD133 expression was significantly correlated with advanced pathological stages (II, III, and IV) in NSCLC.
- CD133 expression was identified as an independent factor for unfavorable prognosis in the studied NSCLC population (HR = 3.157, P = 0.015).
Conclusions:
- CD133 expression is associated with advanced pStage in NSCLC.
- CD133 expression predicts an unfavorable prognosis in patients with pStages II, III, and IV NSCLC.
- CD133 may represent a novel prognostic biomarker for specific stages of NSCLC.
